Insmed's Amikacin Has US FDA Questioning Microbiological Endpoint Vs. Clinical Benefit

 
• By Sue Sutter
  
Gold brass balance scale isolated on white background. Sign of justice, lawyer
US FDA is weighing whether microbiological clearance equals clinical benefit in patients with nontuberculous mycobacterial lung disease.

More from US FDA Performance Tracker

More from Regulatory Trackers